calcium metabolism [pharmacology]
TRANSCRIPT
-
8/12/2019 Calcium metabolism [Pharmacology]
1/28
Pharmacology of CalciumMetabolism
-
8/12/2019 Calcium metabolism [Pharmacology]
2/28
Calcium Metabolism[Calcium & Phosphate homeostasis]
Basic pharmacology Principal Hormonal
Regulators of Bone
Mineral Homeostasis PTH CaPO4
Vit D Both InteractionFGF 23 PO4
Secondary HormonalRegulatorsCalcitonin [ Both ],Glucocorticoids, Estrogen, insulin, GH
Non- HormonalRegulatorsBisphosphonates
CinacalcetPlicamycinThiazides
FluorideStrontium Ranelate
-
8/12/2019 Calcium metabolism [Pharmacology]
3/28
Calcium turnover
-
8/12/2019 Calcium metabolism [Pharmacology]
4/28
Principal regulators ofcalcium and phosphate
homeostasis: (PTH), (FGF23),and vitamin D
Remodeling
_
-
8/12/2019 Calcium metabolism [Pharmacology]
5/28
_
Interaction of principalregulators of calcium/Po4 homeostasis
-
8/12/2019 Calcium metabolism [Pharmacology]
6/28
The hormonal interactions controlling bone mineral homeostasis. In the body ( A),1,25(OH) 2D is produced by the kidney under the control of parathyroid hormone(PTH), which stimulates its production, and fibroblast growth factor 23 (FGF23),which inhibits its production. 1,25(OH) 2D in turn inhibits the production of PTH bythe parathyroid glands and stimulates FGF23 release from bone. 1,25(OH) 2D is the
principal regulator of intestinal calcium and phosphate absorption. At the level ofthe bone ( B), both PTH and 1,25(OH) 2D regulate bone formation and resorption,with each capable of stimulating both processes. This is accomplished by theirstimulation of preosteoblast proliferation and differentiation into osteoblasts, the
bone forming cell. PTH and 1,25(OH) 2D stimulate the expression of RANKL bythe osteoblast, which, with MCSF, stimulates the differentiation and subsequent
activation of osteoclasts, the bone resorbing cell. FGF23 in excess leads toosteomalacia by inhibiting 1,25(OH) 2D3 production and lowering phosphate levels.MCSF, macrophage colony-stimulating factor; OPG, osteoprotegerin; RANKL,ligand for receptor for activation of nuclear factor- B.
-
8/12/2019 Calcium metabolism [Pharmacology]
7/28
-
8/12/2019 Calcium metabolism [Pharmacology]
8/28
CalciumPreparations
Ca chloride-irritant-onlyi.v
Ca gluconate-0.5g tab &
10% i.v. amp.-sense ofwarmth duringinjection[less irritant]
Ca lactate-oral nonirritating
Ca dibasic phosphate andcarbonate-Antacids
Uses Tetany-10ml/10% i.v.
10mts [Ca chloride] Followed by oral calcium
and Vit D Supplement-children ,
pregnancy, Osteoporosis-with other
drugs.[Only Ca and Vit Dnot effective]
Antacids
-
8/12/2019 Calcium metabolism [Pharmacology]
9/28
PTH
-
8/12/2019 Calcium metabolism [Pharmacology]
10/28
Principal regulators of calcium and phosphatehomeostasis:
PARATHYROID HORMONE (PTH)
Increases serum calcium and decreases serum phosphate. Bone formation-
Stimulate proliferation and differentiation of Preosteoblasts to osteoblasts Bone resorption-
PTH acts on the osteoblast to induce a membrane-bound proteincalled RANK ligand (RANK-L ). This factor acts on osteoclasts andosteoclast precursors to increase both the numbers and the activity ofosteoclasts.
These actions increase bone turnover or bone remodeling, -osteoclastic bone resorption and followed by osteoblastic boneformation.
The net effect of excess PTH is to increase bone resorption.
-
8/12/2019 Calcium metabolism [Pharmacology]
11/28
Principal regulators of calcium and phosphatehomeostasis:
PARATHYROID HORMONE (PTH),
PTH in low and intermittent doses increases bone formationwithout first stimulating bone resorption.
Cli ni cal use- r ecombinant PTH (ter iparatide) for the
tr eatment of osteoporosis. Kidney
1. Stimulation of 1,25-dihydroxyvitamin D (1,25[OH] 2D)production .
2. I ncreases reabsorption of calcium and magnesium3. Reduces reabsorption of phosphate , amino acids, bicarbonate,
sodium, chloride, and sulfate.
-
8/12/2019 Calcium metabolism [Pharmacology]
12/28
PTH and 1,25(OH) 2D regulate boneformation and resorption
[remodeling]
Stimulateproliferation anddifferentiation ofPreosteoblasts
StimulateExpression ofRANK-L byOsteoblasts
RANK-L
[R eceptor Activator of Nuclear factor for KB-Ligand]
-
8/12/2019 Calcium metabolism [Pharmacology]
13/28
PTH
Uses: Clinically not used to treat hypocalcimiaExpensive.Parenteral administrationCalcium with Vit D can be used for the same
purpose. Teriparatide[1-34 PTH]-Recombinant
Stimulates bone density[ low and intermittentdoses]
Used in Osteoporosis
-
8/12/2019 Calcium metabolism [Pharmacology]
14/28
FIBROBLAST GROWTH FACTOR 23
[FGF23]
Primary site of production- osteoblasts andosteocytes
Inhibits 1,25(OH) 2D3 production and phosphatereabsorption in the kidney,
Leading to hypophosphatemia and inappropriatelylow levels of circulating 1,25(OH) 2D3
-
8/12/2019 Calcium metabolism [Pharmacology]
15/28
Vit D
Vit D is a hormone?1. Prohormone2. Synthesized in body3. Carried in the blood
4. Acts on target tissues5. Feedback regulation exists
-
8/12/2019 Calcium metabolism [Pharmacology]
16/28
Vit D
Source: Natural-D3 CholecalciferolPlant- D2 Ergocalciferol
Vit D[Natural or Plant]
25[OH]D
1-25[OH]D[Calcitriol]
Liver
Kidney
-
8/12/2019 Calcium metabolism [Pharmacology]
17/28
Vit D
Preparations
Calciferol[D2] Cholecalciferol[D3] Calcitriol[Active form]
Alfacalcidol[1
OHD 3] Analogs of 1,25(OH) 2D
Calcipotriol [Psoriasis]Doxercalciferol and Paricalcitol
Uses
Prophylaxis and treatment ofVit D deficiency
Metabolic rickets Renal rickets[Alfacalcidol] Osteoporosis Hypoparathyroidism
Drug interactions Cholestyramine Phenytoin & Phenobarbitone-
Reduce action on target tissues
Prophylaxis -(400 IU/day)Treatment-(4000IU/ day)
Alfacalcidol[1 OHD 3
-
8/12/2019 Calcium metabolism [Pharmacology]
18/28
INTERACTION OF PTH, FGF23, & VITAMIN D
-
8/12/2019 Calcium metabolism [Pharmacology]
19/28
Secondary hormone regulators-Calcitonin
Secreted by the parafollicular cells of the thyroid Lowers serum calcium and phosphate by actions on bone and kidney. Calcitonin
inhibits osteoclastic bone resorption.
In the kidney-reduces both calcium and phosphate reabsorption as well asreabsorption of -Na, K, and Mg.
Decreases gastrin secretion and reduces gastric acid output while increasing secretion ofsodium, potassium, chloride, and water in the gut.
In the adult human, no readily demonstrable problem develops in cases of calcitonindeficiency (thyroidectomy) or excess (medullary carcinoma of the thyroid).
Useful drug for the treatment of Paget's disease, hypercalcemia, and osteoporosis.
-
8/12/2019 Calcium metabolism [Pharmacology]
20/28
Non- Hormonal Regulatorsof Bone mineral homeostasis
BisphosphonatesCinacalcet
PlicamycinThiazidesFluoride
Strontium Ranelate
-
8/12/2019 Calcium metabolism [Pharmacology]
21/28
WHAT ARE BISPHOSPHONATES?
Bisphosphonates are small inorganic molecules Bind to a substance called hydroxyapatite on the
surface of bones. Osteoclasts are inhibited and destroyed. Bisphosphonates reduce bone resorption
-
8/12/2019 Calcium metabolism [Pharmacology]
22/28
Bisphosphonates
Non-Nitrogenous[I Gen] Etidronate- 1 Clodronate 10 Tiludronate - 10
Nitrogenous[II Gen]
Pamidronate [i.v.only] 100 Neridronate - 100 Olpadronate - 500 Alendronate - 500 [5-10mg daily/35-70 mg weekly]
Ibandronate - 1000
[III Gen] Risedronate 2000 Zoledronate -[i.v.] 10000
-
8/12/2019 Calcium metabolism [Pharmacology]
23/28
BisphosphonatesMOA
Non-Nitrogenous Structure-similar to
pyrophosphate Accumulates within the
osteoclasts and promote theirapoptosis.
Prevents bone
resorption
Nitrogenous Inhibit farnesyl diphosphate synthase,
an enzyme in the mevalonate pathway. Inhibition of this enzyme prevents the
synthesis signalling proteins necessaryin the formation of the ruffled border
Prevents attachment of osteoclasts to bone-
Prevents bone
resorption
-
8/12/2019 Calcium metabolism [Pharmacology]
24/28
i h h
-
8/12/2019 Calcium metabolism [Pharmacology]
25/28
BisphosphonatesPK
Oral absorption is poor[5-10%] Affected by milk Excreted by kidney Highly concentrated in bones and remains for years
Bi h h
-
8/12/2019 Calcium metabolism [Pharmacology]
26/28
BisphosphonatesADE
Oesophagitis- Prevented by remaining seated upright for 30 to 60
minutes after taking the medication with a glass ofwater
Intravenous bisphosphonates -fever and flu-likesymptoms
Associated with osteo-necrosis of the jaw Rarely # of long bones
-
8/12/2019 Calcium metabolism [Pharmacology]
27/28
Clinical uses of bisphosphonates
Prevention or treatment of postmenopausalosteoporosis
Paget's disease of bone. Hypercalcaemia caused by malignant disease. Prevention or treatment of glucocorticoid-
induced osteoporosis. Under investigation for the treatment of cancer
metastases in bone
-
8/12/2019 Calcium metabolism [Pharmacology]
28/28
Osteoporosis Abnormal loss of bone predisposing to fractures.
Most common in postmenopausal women but also occurs in men
Regular ex Diet Ca and Vit D
supplements Bisphosphonates-
Oral/i.v.
Teriparatide
SERM-Raloxifene Calcitonin Strontium Denosumab[Anti
RANKL antibody] HRT not recommended